Please login to the form below

Not currently logged in
Email:
Password:

CC-486

This page shows the latest CC-486 news and features for those working in and with pharma, biotech and healthcare.

BMS’ oral maintenance therapy boosts survival in AML patients

BMS’ oral maintenance therapy boosts survival in AML patients

We now look forward to taking the next steps to bring CC-486 to eligible AML patients in need,” he added. ... According to a statement issued by BMS, regulatory submissions for CC-486 are planned for the first half of 2020.

Latest news

  • Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial

    The formulation – known as CC-486 – is an orally-active version of Vidaza, Celgene’s already-marketed azacitidine product which is administered intravenously. ... The new  QUAZAR AML-001 study compared CC-486 to placebo as a maintenance therapy

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....